INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is caused by a lentivirus, HIV, which primarily infects the CD4+ T lymphocytes and monocytes/macrophages. Since the continuous proliferation and differentiation of a relatively small number of hematopoietic stem cells maintains all of the target cell types infected by HIV, introduction of a therapeutic gene(s) into hematopoietic stem cells is expected to confer long-term protection. Alternatively, delivering a therapeutic gene to the peripheral blood T lymphocytes may restore some degree of general immune functions. Both T lymphocytes and stem cells are therefore being considered for use in anti-HIV-1 gene therapy. Various anti-HIV-1 genes that are being considered for this purpose include interfering RNAs (i.e. antisense RNAs, sense RNAs, ribozymes) and interfering proteins (i.e. transdominants mutants, targeted nucleases) (4-7). However, most anti-HIV-1 genes, including several that are currently being evaluated in clinical trials, confer only partial inhibition of HIV-1 replication. Therefore, further development and testing of genes conferring complete protection is warranted. These genes must be designed to inhibit HIV-1 replication for a sustained period of time, while preventing the emergence of escape mutants of HIV-1 through mutations or recombinations. For the eventual reconstitution of a functional immune system, it is also crucial to focus on genes that would confer a positive survival advantage to the gene-modified cells, without perturbing their normal immune functions.
Hammerhead ribozymes are small catalytic RNAs that can be designed to specifically bind to and cleave the target RNA molecules in trans (6, 8, 9) . Moloney murine leukemia virus (MoMuLV)-based vectors were used in a number of studies to express ribozymes targeted against various sites within the HIV-1 RNA. A varying degree of inhibition of HIV-1 replication was reported using mostly monomeric, and in some cases dimeric ribozymes (6) . A MoMuLV-based vector was designed in our laboratory to allow constitutive and Tatinducible expression of a multimeric hammerhead ribozyme, Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] . This multimeric ribozyme is targeted against nine highly conserved sites within the env coding region of HIV-1 RNA (1, 2) . Since these sites are only conserved in the clade B of HIV-1, Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] would not be effective in patients infected with other clades of HIV-1. Although the emergence of an HIV-1 escape mutant through point mutations is highly unlikely (as this would require HIV to mutate nine conserved sites within a single gene), a single recombination event between different clades of HIV-1 could confer resistance to all nine ribozymes in Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] . Thus, another multimeric ribozyme, Rz [10] [11] [12] [13] [14] , was designed in this study. This multimeric ribozyme is targeted against five sites that are highly conserved amongst all major clades of HIV-1. A high degree of conservation of these target sites should make it very unlikely for an escape mutant of HIV-1 to emerge through mutations or recombinations. These two multimeric ribozymes were also combined to yield Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The mouse stem cell virus (MSCV)-based MGIN vector (3) was used to express the three multimeric hammerhead ribozymes. We report here, the design and construction of these multimeric ribozymes, the development of MGINbased vectors expressing these ribozymes, the activity of multimeric ribozymes produced in the stable MT4 (a human CD4+ T lymphoid cell line) transductants, and the degree of inhibition of HIV-1 replication achieved.
MATERIALS AND METHODS

Construction of retroviral vectors
All ribozyme-encoding sequences were cloned in the MSCV-based MGIN vector (3) , between the enhanced green fluorescence protein (egfp) gene and the internal ribosome entry site (IRES). All clones were identified and confirmed by restriction enzyme and PCR analyses. Before proceeding with the vector constructions, unique Csp451 and BglII sites were introduced 3' to the egfp gene. To this end, the EGFP-F primer (5'-GGA-TCC-GAA-TTC-GCC-AGC-ATG-GTG-AGC-AAG-GGC-GAG-GAG-3'; containing the EcoRI site) and the EGFP-R primer (5'-GCT-CGA-GGC-GGC-CGC-GGG-TGG-AGA-TCT-AGG-GCT-TTC-GAA-TTA-ATC-ATT-ACT-TGT-ACA-GCT-CGT-CCA-TGC-CGA-3'; containing the Csp451, BglII and NotI sites) were used to PCR amplify the egfp gene from the MGIN vector, as described earlier (10). The PCR product was then digested with EcoRI and NotI and cloned at the corresponding sites within the MGIN vector. The resulting vector was used in the subsequent cloning experiments. [1] [2] [3] [4] [5] [6] [7] [8] [9] vector construction: MoTiN-Rz 1-9 contains a NotI site within the Rz 1-9 region. This site was first inactivated as follows. MoTiN-Rz 1-9 was digested with the NotI enzyme. The ends were then filled using Klenow, and the DNA was religated and transformed into E. coli. The modified MoTiN-Rz 1-9 vector was then used as a template for PCR amplification of Rz 1-9 using the Rz 1-9 -F primer (5'-AGA-TCT-ATC-GAT-GGA-TCT-AAT-ATG-CCA-TAA-TAC-TG-3'; containing the ClaI site) and the  Rz 1-9 -R primer (5'-GTT-CGA-AAG-ATC-TCG-CGT-ACT-AGT-AGC-AAT-G-3' ; containing the BglII site). The PCR product was then digested with ClaI and BglII, and cloned within the MGIN vector at the compatible Csp451 and BglII sites downstream of the egfp gene. [10] [11] [12] [13] [14] vector construction: HIV-1 target sites for the individual ribozymes within the Rz 10-14 are as follows: the Rz 10 target site, 5'-AUU-GGG-GUC 5254 -UGC-AUA-CA-3'; the Rz 11 target site, 5'-GGG-GCA-GUA 4976 -GUA-AUA-CA-3'; the Rz 12 target site, 5'-UUU-CGG-GUU 4904 -UAU-UAC-AG-3'; the Rz 13 target site, 5'-ACA-CCU-GUC 2498 -AAC-AUA-AU-3'; and the Rz 14 target site, 5'-ACU-CUG-GUA 586 -ACU-AGA-GA-3'. The cleavage occurs after the GUC/U/A sequence, shown in bold. The nucleotide C/U/A within the HIV-1 RNA after which the cleavage occurs is numbered; the first nucleotide of the HIV-1 (NL4-3) provirus DNA denotes +1. All of these target sites were selected on the basis of 100% sequence conservation amongst all major clades of HIV-1 (11).
MGIN-Rz
The primers used to construct Rz 10-14 are as follows: Rz 14 F, 5'-GCA-GAT-CTA-ATC-GCA-AGG-ATC-CGG-CCC-ATA-TGG-CCT-CTC-TAG-TCT-GAT-GAG-TCC-GTG-AGG-ACG-AAA-CCA-GAG-TCC-GCG-GAT-TAT-3'; Rz 13 R, 5'-TAT-TAC-AGA-GGC-CTA-CAC-CTG-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGA-ACA-TAA-TCC-GCG-GAC-TCT-G-3'; Rz 11-12 R, 5'-CAT-ACA-ATG-CAT-GGG-TCA-GTT-TCG-TCC-TCA-CGG-ACT-CAT-CAG-GTA-ATA-CAT-CCG-GAT-TTC-GGG-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGT-ATT-ACA-GAG-GCC-TAC-A-3'; and Rz 10 R, 5'-GGA-TAG-CGA-TCG-ATG-GCC-ATA-TGG-GCC-ATT-GGG-GTG-TCG-TCC-TCA-CGG-ACT-CAT-CAG-TGC-ATA-CAA-TGC-ATG-GGG-C-3'. The Rz 14 F and Rz 13 R primers were PCR amplified to yield a product, which was PCR amplified with the Rz 11-12 R primer to yield another PCR product, which was then PCR amplified with the Rz 10 R primer to yield the final 280 bp PCR product containing Rz [10] [11] [12] [13] [14] . All PCRs were performed as described earlier (12) . Starting from the 5' end, the order of various ribozymes in this multimeric hammerhead ribozyme is Rz 14 , Rz 13 , Rz 12 , Rz 11 , and Rz 10 . For these ribozymes to meet their target sites within the HIV-1 RNA in a contiguous fashion, it would have been better to have them in a reverse order. Thus, at this stage, to partially reverse this order to Rz 10 , Rz 13 , Rz 12 , Rz 11 , and Rz 14 , the final PCR product was PCR amplified using the Rz 10 F primer (5'-ATC-GAT-AGA-TCT-GTA-TGC-ACT-GAT-GAG-TCC-GTG-AGG-ACG-AAA-CCC-CAA-TGG-GCC-CGC-GGA-TTA-TGT-TCT-G-3'; containing the BglII site, Rz 10 , and a 17-nucleotide overlap) and the Rz 14 R primer (5'-GGA-TCC-GCG-GCC-GCT-TCG-AAC-TCT-GGT-TTC-GTC-CTC-ACG-GAC-TCA-TCA-GAC-TAG-AGA-ATG-CAT-GGG-GCA-GTT-TC-3'; containing a 17-nucleotide overlap, Rz 14 , and the NotI site). The resulting product was digested with BglII and NotI, and cloned at the same sites within the MGIN vector to yield MGIN-Rz [10] [11] [12] [13] [14] .
MGIN-Rz 1-14 vector construction:
The EcoRIBglII fragment of MGIN-Rz 1-9 (containing the egfp gene and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] ) was cloned into the EcoRI and BglII sites within the MGIN-Rz 10-14 vector. In the resulting vector, the egfp gene in the MGIN-Rz 10-14 was replaced with the egfp gene and Rz 1-9 .
Transduction and selection of stable MT4 transductants
Amphotropic MGIN (as a control), MGIN-Rz 1-9 , MGIN-Rz [10] [11] [12] [13] [14] , and MGIN-Rz 1-14 vector particles were produced (13) and were used to transduce the MT4 cells (14, 15) , as described previously (13, 16) . The pools of G418 resistant stable MT4 transductants were each selected for three weeks and were used in the subsequent experiments.
PCR analysis of genomic DNA from stable MT4 transductants
Genomic DNA was extracted from the individual pools of stable MT4 transductants expressing the multimeric ribozymes (17) . PCRs were performed for 40 cycles (1 min at 95°C, 1 min at 56°C, and 1 min at 72°C each), as described previously (18), using MGIN-F (5'-CTC-TCG-GCA-TGG-ACG-AG-3') and MGIN-R (5'-ATG-CTG-GTC-AAG-AAG-AC-3') primers which bind to the vector sequences upstream and downstream of the multimeric ribozyme cloning site. Gap-5' (5'-TCT-ACT-GGC-GCT-GCC-AAG-3') and Gap-3' (5'-TCT-AGA-CGG-CAG-GTC-AGG-3') primers were used as a control to amplify the cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. The PCR products were analyzed by electrophoresis on a 1.5% agarose gel.
RT-PCR analysis of total RNA from stable MT4 transductants
Total RNA was extracted from stable MT4 transductants using acid guanidium thiocyanate-phenolchloroform extraction (19) . The RNA was then incubated with RQI RNase-free DNase (Promega Corp.; Madison, WI) for 15 min at 37°C to degrade any residual DNA. To ensure that the DNase treatment was complete, RNA samples were analyzed by PCR using the Gap-5'/Gap-3' primer pair. Semi-quantitative RT-PCRs were then performed as described previously (20) . Reverse transcriptions were performed using the Neo-3' (5'-CTC-TTC-GTC-CAG-ATC-ATC-3') and Gap-3' primers. The cDNAs were then PCR amplified using the Neo-5' (5'-CAA-GAC-CGA-CCT-GTC-CGG-3') and 32 P-labelled Neo-3' primer pair and (as a control) the Gap-5' and 32 Plabelled Gap-3' primer pair; the 3' primers were 5'-end labeled (~1.3 x 10 9 cpm/mg) using [gamma 32 P] ATP (Amersham; 6000 Ci/mmol), as described previously (10) . To ensure that a linear relationship exists between the input cDNA concentration and the intensity of the PCR products, the concentration of the 5' and the 32 P-labeled 3' primers was increased to 5 mg/l and the PCRs were performed for 25 cycles. Control PCRs were done to make sure that these conditions allow semi-quantitative amplification. To this end, the Neo-5' and the 32 P-labeled Neo-3' primers were used to PCR amplify 10 to 1,000,000 copies of MGIN vector DNA and the Gap-5' and the 32 P-labeled Gap-3' primers were used to PCR amplify 0.1 and 0.5 mg/l of cellular genomic DNA (20) . The RT-PCR and PCR products were analyzed on a 2% agarose gel, followed by autoradiography.
In vitro cleavage activity of multimeric ribozymes amplified from pools of stable MT4 transductants
Total cellular RNA extracted from the MT4 transductants expressing Rz 1-9 , Rz 10-14 , or Rz 1-14 was RT-PCR amplified, as described previously (18) , to generate templates enabling T7-promoter driven transcription of multimeric ribozymes. Reverse transcription was performed using the MGIN-R primer. The cDNA was then used in a PCR using a T7-MGIN-F primer (5'-ATA-TCA-TAT-GTA-ATA-CGA-CTC-ACT-ATA-GGG-CGA-CTC-TCG-GCA-TGG-ACG-AG-3'; containing the T7 promoter) and the MGIN-R primer. The PCR products were then transcribed in vitro using the T7 RNA polymerase (Life Technologies; Burlington, Canada) as described earlier (18) . The reactions were stopped after 2 h by digesting the template DNA with 5 U of RQI RNasefree DNase for 10 min at 37°C. The RNA was extracted once with phenol and then ethanol precipitated.
The pNL4-3 DNA was PCR amplified to yield T7 promoter-containing templates, which were in vitro transcribed to generate alpha 32 P-labelled target RNAs as described previously (12) . T7-Env-5' (5'-ATA-TCA-TAT-GTA-ATA-CGA-CTC-ACT-ATA-GGG-CGA-GAA-GGA-GAA-ATA-TCA-GC-3') and Env-3' (5'-TCA-CTT-CTC-CAA-TTG-TCC-3') primers were used to yield a 1400 ntlong alpha 32 P-labelled T 1-9 target RNA containing the Rz 1-9 cleavage sites. T7-Pol-5' (5'-ATA-TCA-TAT-GTA-ATA-CGA-CTC-ACT-ATA-GGG-CGA-CTC-TCG-GCA-TGG-ACG-AGG-GAC-GTG-ACA-TGG-GGG-G-3') and Vif-3' (5'-TTT-CTT-ATA-GCA-GAT-TC-3') primers were used to yield a 602 nt-long alpha 32 P-labelled T 10-12 target RNA containing the Rz 10 , Rz 11 , and Rz 12 cleavage sites. T7-Pro-5' (5'-ATA-TCA-TAT-GTA-ATA-CGA-CTC-ACT-ATA-GGG-CGA-CAA-CTA-AAG-GAA-GCT-CTA-3') and Pro-3' (5'-TGC-GGC-CGC-AAT-TGG-AGG-3') primers were used to yield a 413 nt-long alpha 32 P-labelled T 13 target RNA containing the Rz 13 cleavage site. T7-leader-5' (5'-AAA-TTA-ATA-CGA-CTC-ACT-ATA-GGG-TCT-CTC-TGG-TTA-GA-3') and leader-3' (5'-CAA-GTC-CCT-GTT-CGG-GC-3') primers were used to yield a 200 nt-long alpha 32 P-labelled T 14 target RNA containing the Rz 14 cleavage site.
The resulting Rz 1-9 , Rz 10-14 , and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] RNAs and the alpha 32 P-labelled T 1-9 , T 10-12 , T 13 , and T 14 target RNAs were used in the trans cleavage reactions as described previously (1, 18) . Essentially, multimeric ribozymes and target RNAs were combined in a reaction mixture containing 40 mM Tris-Cl, pH 8.0, and 10 mM NaCl. The samples were heated to 65°C for 5 min, cooled to 37°C, and the cleavage reaction initiated by adding 20 mM MgCl 2 . After incubation for 2 h at 37°C, the reaction was stopped by adding 5 mM EDTA. Samples containing the 1400 nt-long alpha 32 P-labelled T 1-9 RNA and its cleavage products were loaded onto a 8 M urea-6% polyacrylamide gel and the electrophoresis performed for 1 h at 750 Volts. The alpha 32 P-labelled T 10-12 , T 13 , and T 14 RNAs and their cleavage products were then loaded and the electrophoresis continued for another 45 min at 750 Volts. The gel was then exposed to an XAR-5 X-ray film (Kodak, Toronto, Canada).
HIV-1 susceptibility of stable MT4 transductants
Stable MT4 transductants were challenged with the HIV-1 strain NL4-3 (21) . Challenge experiments were performed as described previously (16, 22) , except that the challenge virus stock was produced as follows. HIV-1 was harvested every day (rather than every third day) by collecting the entire cell culture supernatant (rather than collecting half of the cell culture supernatant), and only the sample that contained the highest virus concentration (rather than all samples that contained virus) was aliquoted and used. The titer of this virus (infectious units/ml) was determined using U373-MAGI-CXCR4 CEM cells (23) .
The pools of actively dividing stable MT4 transductants (2 x 10 6 cells) were each inoculated with the HIV-1 strain NL4-3. HIV-1 inoculations were performed at a multiplicity of infection (m.o.i.) of 0.5 and 0.05 for 2 hours at 37 o C, with gentle shaking (16, 22) . Cells were washed twice with the RPMI 1640 medium, and resuspended in the same medium. Cells were then cultured at 37 o C. Cells were routinely inspected for syncytia formation. The culture supernatants were collected every third day and replaced with the fresh medium. Experiments were terminated after 60 days. The amount of HIV-1 p24 antigen present in the frozen cell culture supernatants was then measured by an enzyme linked immunosorbent assay using a Kit (Abbott; Chicago, IL). For OD 492 values >2.0, samples were diluted 10-to 5000-fold and retested. The OD 492 values ranging between 0.1 to 1.9 were then multiplied with the dilution factor and converted to pg of p24 antigen per ml.
RESULTS
The MSCV-based MGIN vector was used to express the three multimeric hammerhead ribozymes, Rz 1-9 , Rz 10-14 , and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . These vectors were then tested in MT4 cells for the level of expression, ribozyme activity, and inhibition of HIV-1 replication.
MGIN-based retroviral vectors expressing multimeric ribozymes, Rz 1-9 , Rz 10-14 , or Rz 1-14
The multimeric ribozyme Rz 1-9 is targeted against nine highly conserved sites within the env coding region of HIV-1 RNA (clade B) (1, 2). Rz 10-14 was designed against one site within the vif coding region, two sites within the pol coding region, one site within the pro coding region, and one site within the 5' leader sequence of HIV-1 RNA. All five of these target sites were identified on the basis of sequence conservation amongst all major clades of HIV-1. Overlapping PCRs using synthetic oligodesoxynucleotides were performed to assemble Rz [10] [11] [12] [13] [14] . The two multimeric hammerhead ribozymes were also combined to yield Rz 1-14 .
The MGIN vector (3) used to express these ribozymes contains the egfp gene, an IRES element from the encephalomyocarditis virus, and the neomycin phosphotransferase (neo) gene (Figure 1 ). The MSCV 5' long terminal repeat (LTR) promoter-driven bicistronic transcript allows translation of both open reading frames. Genes encoding the three multimeric hammerhead ribozymes were cloned between the egfp gene and the IRES element.
Development of pools of stable MT4 transductants expressing multimeric ribozymes
Amphotropic MGIN, MGIN-Rz 1-9 , MGIN-Rz [10] [11] [12] [13] [14] , and MGIN-Rz 1-14 vector particles were each used to transduce a human CD4+ T lymphoid (MT4) cell line (14, 15) . Pools of G418 resistant stable MT4 transductants were then selected and tested without cloning.
The presence of DNA sequences encoding the multimeric ribozymes was confirmed by PCR analysis of genomic DNA isolated from various MT4 transductants. The MGIN-F/MGIN-R primer pair was used for this purpose. These primers were designed against sequences upstream (within the egfp gene) and downstream (within the IRES element) of the ribozyme-cloning site. PCR products obtained from untransduced (as a control) and transduced cells are shown in figure 2a. No PCR product was detected in the untransduced sample ( figure 2a, lane 1) . 217, 626, 497, and 906 bp products were detected in the MGIN, MGIN-Rz 1-9 , MGIN-Rz 10-14 , and MGIN-Rz 1-14 vector-transduced samples, respectively (figure 2a, lanes 2-5). Genomic DNA from the untransduced and transduced cells was also analyzed using the Gap-5'/Gap-3' primer pair. As expected, a 122 bp product specific for the cellular GAPDH gene was detected in the untransduced and transduced samples ( figure 2b, lanes 1-5) .
Vector RNA expression from the 5 ' LTR promoter was confirmed by RT-PCR analysis of total cellular RNA from various MT4 transductants. Reverse transcriptions were performed using the Neo-3' and Gap-3' primers, followed by PCRs which were performed using the Neo-5'/ . This primer pair was used to amplify a 122 bp region within the endogenous GAPDH gene, which served as an internal control to assure that an equal amount of total RNA was analyzed in all cases. Control PCRs were performed using 100 (lane 6) and 500 (lane 7) ng of total cellular DNA. PCR product sizes are indicated by an arrow.
quantitative conditions allowing a linear relationship between the target RNA concentration and the RT-PCR product intensity (Figure 3a, lanes 6-11; figure 3b, lanes   6,7) . A semi-quantitative RT-PCR using the Neo-5'/ 32 Plabelled Neo-3' primer pair resulted in the amplification ofa 330 bp product. RT-PCR products of similar intensities were obtained for all transduced samples (figure 3a, lanes 2-5), suggesting similar expression levels in all MT4 transductants. No RT-PCR product was obtained for the untransduced sample ( figure 3a, lane 1) . The Gap-5'/ 32 Plabelled Gap-3' primer pair was used as a control and yielded the expected 122 bp product in all untransduced and transduced samples ( figure 3b, lanes 1-5) . RNA samples were also analyzed by PCR using the Gap-5'/Gap-3' primer pair to ensure the lack of DNA contamination (results not shown).
In vitro cleavage activity of multimeric ribozymes produced from the stable MT4 transductants
To demonstrate the activity of the multimeric ribozymes produced in the transduced MT4 cells, Rz 1-9 , Rz 10-14 , and Rz 1-14 were amplified from the cellular RNA by RT-PCR using a 5' primer, which contained the T7 promoter. The RT-PCR products were then transcribed in vitro to yield Rz 1-9 , Rz 10-14 , and Rz 1-14 , which were used in trans cleavage reactions. The cleavage reactions were performed in the presence of alpha 32 P-labelled T 1-9 RNA (containing the Rz 1-9 target sites), T 10-12 RNA (containing the Rz 10 , Rz 11, and Rz 12 target sites), T 13 RNA (containing the Rz 13 figure 4b, lane 7) yield the 228 and 185 bp products, confirming the activity of Rz 13 in both of these multimeric ribozymes. T 14 RNA cleavage by Rz 10-14 (figure 4b, lane 2) or Rz 1-14 (figure 4b, lane 6) was expected to yield 129 and 71 bp products, which were not detected. This ribozyme was therefore inactive. These results demonstrate that except for Rz 14 targeted against the 5' leader sequence, the ribozymes present within the three multimeric ribozymes produced in MT4 transductants are active.
Cleavage reactions were performed using 1400, 602, 413, and 200 nt-long target RNAs, which were subject to cleavage by the multimeric ribozymes containing nine, five, or fourteen monomeric ribozymes (figure 4b). Only the cleavage products of the expected sizes were detected, and no additional products were detected upon cleavage by Rz 1-9 , Rz 10-14 and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Therefore, these results also demonstrate the target RNA specificity of these ribozymes.
HIV-1 susceptibility of pools of stable MT4 transductants expressing multimeric ribozymes
Stable MT4 transductants lacking or expressing Rz 1-9 , Rz 10-14 , or Rz 1-14 were each challenged with HIV-1 (figure 5b). Thus, the combined ribozyme Rz 1-14 confers the best inhibition, followed by Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] , and then Rz 10-14 .
DISCUSSION
We have previously shown that a multimeric hammerhead ribozyme targeted against nine highly conserved sites within the env coding region of HIV-1 RNA confers excellent inhibition of HIV-1 replication (1). Since all nine of these sites are highly conserved within the clade B of HIV-1, it is unlikely that an escape mutant of HIV-1 could emerge through point mutations during reverse transcription. However, none of these sites is conserved amongst other HIV-1 clades. Thus, recombination in patients infected with multiple clades could easily result in an escape mutant of HIV-1 that would not be inhibited by any of the nine ribozymes present in Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] . Therefore, we designed another multimeric ribozyme, Rz [10] [11] [12] [13] [14] . Rz 10 is targeted against one site within the vif coding region. Rz 11 and Rz 12 are targeted against two sites within the pol coding region. Rz 13 is targeted against one site within the pro coding region. And, Rz 14 is targeted against one site within the 5' leader region of HIV-1 RNA. These sites were selected on the basis of 100% sequence conservation amongst all major clades of HIV-1. Such a high degree of sequence conservation across clades suggests that mutations in these target sites would be detrimental to HIV-1 replication. Thus, it is anticipated that in addition to conferring protection against all major clades of HIV-1, this ribozyme would greatly decrease the possibility of the emergence of a viable escape mutant of HIV-1 through point mutations or recombinations. The two multimeric ribozymes, Rz 1-9 and Rz 10-14 , were also combined to yield Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Rz 1-14 was expected to confer an even greater degree of protection.
Previously, a MoMuLV-based MoTiN vector (2) was used to express Rz 1-9 (1). In this vector, the multimeric ribozyme was expressed as part of transcripts produced from the 5' LTR promoter and an internal tk-TAR fusion promoter. The tk-TAR promoter was designed to allow constitutive gene expression in uninfected cells, and highlevel Tat-inducible gene expression in the HIV-infected cells. Excellent inhibition of HIV-1 replication was observed in transduced MT4 cells (1) . However, only partial inhibition of virus replication was observed in transduced peripheral blood T lymphocytes challenged with the laboratory or clinical isolates of HIV-1 (24) .
Recent studies using the MoMuLV-based vectors have demonstrated that gene expression from the 5' LTR promoter is downregulated upon differentiation of transduced hematopoietic stem cells. Downregulation of gene expression seems to result from de novo methylation of the LTR and binding of negative regulatory transcription factors to the LTR and the primer-binding site (25) . In the MSCV-based vectors, the LTR and the 5' untranslated sequences were modified to overcome these problems (26) (27) (28) . These vectors were shown to maintain gene expression following differentiation of human hematopoietic stem cells (3, 26, 29, 30) . Therefore, the multimeric hammerhead ribozymes were expressed using the MSCV-based MGIN vector (3) . This vector contains the neo gene, the IRES Amphotropic vector particles were used to transduce a human CD4+ T lymphoid MT4 cell line. Pools of G418 resistant stable MT4 transductants were shown to contain ribozyme sequences by PCR analysis. Analysis of total cellular RNA under semi-quantitative RT-PCR conditions revealed similar level of interfering RNA production in all MT4 transductants. With the exception of Rz 14 (targeted against the 5' leader sequence), all individual ribozymes within the three multimeric ribozymes tested were shown to be active. As the DNA sequences encoding the multimeric ribozymes were assembled by PCR, a mutation during PCR might have inactivated Rz 14 . Production of multimeric ribozymes used during the cleavage reactions also involved an RT-PCR step. However, it is highly unlikely that a mutation during RT-PCR inactivated Rz 14 in both Rz [10] [11] [12] [13] [14] and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Our results also demonstrate that it is possible to use retroviral vectors to express up to fourteen different ribozymes. As each ribozyme contained the same 22 ntlong catalytic domain, a deletion during reversetranscription could have eliminated some or all of the ribozymes. In the case of the MoMuLV-based double copy vector containing only a 16 nt-long duplication within the 3' LTR, inserted sequences were shown to be deleted by others (31) and us (Medina and Joshi, unpublished results).
Cells expressing the multimeric hammerhead ribozymes were viable and showed no sign of toxicity. As MoTiN-Rz 1-9 was previously shown to confer excellent inhibition of HIV-1 replication, we were concerned that in the current study it will not be easy to determine which of the three multimeric hammerhead ribozymes confers the best protection. Thus, the HIV-1 used in these challenge experiments was produced by using a different procedure to ensure that it is highly infectious. Inhibition of virus replication was measured at a m.o.i of 0.05 and 0.5. In these experiments, Rz 1-14 conferred the best protection, followed by Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] , and then Rz [10] [11] [12] [13] [14] .
These results demonstrate t he feasibility of a multimeric hammerhead ribozyme-based strategy to successfully inhibit HIV-1 replication using the MGIN vector. Experiments are now underway to test these vectors against challenge with all major clades of HIV-1. These vectors will also be tested for inhibition of HIV-1 replication in transduced peripheral blood T lymphocytes and in the progeny of transduced CD34+ stem cells. As these multimeric hammerhead ribozymes are targeted against all major clades of HIV-1, it is anticipated that they would provide benefit to HIV-positive patients worldwide.
